Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

STAT3 and epithelial-mesenchymal transitions in carcinomas.

Wendt MK, Balanis N, Carlin CR, Schiemann WP.

JAKSTAT. 2014 Jan 1;3(1):e28975. doi: 10.4161/jkst.28975. Epub 2014 Apr 29. Review.

2.

Mechanism and preclinical prevention of increased breast cancer risk caused by pregnancy.

Haricharan S, Dong J, Hein S, Reddy JP, Du Z, Toneff M, Holloway K, Hilsenbeck SG, Huang S, Atkinson R, Woodward W, Jindal S, Borges VF, Gutierrez C, Zhang H, Schedin PJ, Osborne CK, Tweardy DJ, Li Y.

Elife. 2013 Dec 31;2:e00996. doi: 10.7554/eLife.00996.

3.

Tuning of alternative splicing--switch from proto-oncogene to tumor suppressor.

Shchelkunova A, Ermolinsky B, Boyle M, Mendez I, Lehker M, Martirosyan KS, Kazansky AV.

Int J Biol Sci. 2013;9(1):45-54. doi: 10.7150/ijbs.5194. Epub 2012 Dec 19.

4.
5.
6.

Estrogen and progesterone are critical regulators of Stat5a expression in the mouse mammary gland.

Santos SJ, Haslam SZ, Conrad SE.

Endocrinology. 2008 Jan;149(1):329-38. Epub 2007 Sep 20.

7.

Human 3beta-hydroxysteroid dehydrogenase types 1 and 2: Gene sequence variation and functional genomics.

Wang L, Salavaggione E, Pelleymounter L, Eckloff B, Wieben E, Weinshilboum R.

J Steroid Biochem Mol Biol. 2007 Oct;107(1-2):88-99. Epub 2007 Jun 8.

8.

STAT5 isoforms: controversies and clarifications.

Ramos HL, O'Shea JJ, Watford WT.

Biochem J. 2007 May 15;404(1):e1-2.

9.

Key stages in mammary gland development. Secretory activation in the mammary gland: it's not just about milk protein synthesis!

Anderson SM, Rudolph MC, McManaman JL, Neville MC.

Breast Cancer Res. 2007;9(1):204. Review.

10.
11.
12.
13.
16.

Comparison of the transactivation domains of Stat5 and Stat6 in lymphoid cells and mammary epithelial cells.

Moriggl R, Berchtold S, Friedrich K, Standke GJ, Kammer W, Heim M, Wissler M, Stöcklin E, Gouilleux F, Groner B.

Mol Cell Biol. 1997 Jul;17(7):3663-78.

17.

Activation of different Stat5 isoforms contributes to cell-type-restricted signaling in response to interferons.

Meinke A, Barahmand-Pour F, Wöhrl S, Stoiber D, Decker T.

Mol Cell Biol. 1996 Dec;16(12):6937-44.

18.

Naturally occurring dominant negative variants of Stat5.

Wang D, Stravopodis D, Teglund S, Kitazawa J, Ihle JN.

Mol Cell Biol. 1996 Nov;16(11):6141-8.

19.

Deletion of the carboxyl-terminal transactivation domain of MGF-Stat5 results in sustained DNA binding and a dominant negative phenotype.

Moriggl R, Gouilleux-Gruart V, Jähne R, Berchtold S, Gartmann C, Liu X, Hennighausen L, Sotiropoulos A, Groner B, Gouilleux F.

Mol Cell Biol. 1996 Oct;16(10):5691-700.

Supplemental Content

Support Center